


 Cite this: *Chem. Commun.*, 2023, 59, 5419

 Received 11th February 2023,  
Accepted 11th April 2023

DOI: 10.1039/d3cc00638g

rsc.li/chemcomm

## VITAS, a sensitive *in vivo* selection assay to discover enzymes producing antiviral natural products†

 Aws Fahd Alharbi, Hayun Kim, Dhirish Chumroo, Yuxuan Ji, Mohammed Hakil and Kourosh H. Ebrahimi \*

**To discover new broad-spectrum antiviral nucleotide analogues from natural resources or through protein engineering, we have developed a sensitive *in vivo* selection assay named Viral polymerase-Inhibition Toxin-Associated Selection (VITAS). We show that the assay works with enzymes from three Kingdoms of life.**

There has been a rise in the emergence and re-emergence of new viruses like Zika, SARS, SARS-CoV-2, and Ebola.<sup>1</sup> Therefore, we need to discover and develop new antiviral therapeutics. Natural products (NPs), the secondary metabolites produced by enzymes in various organisms, are an unlimited resource for finding new antiviral lead molecules.<sup>2,3</sup> Between 1980 and 2010, more than 60% of drugs were derived from NPs.<sup>4</sup> A prominent example of drugs originating from NPs is the antiviral nucleotide/nucleoside analogues (ANAs).<sup>5–7</sup> Some of the earliest bioactive nucleoside analogues, *e.g.* pongosine, spongothymidine, and spongouridine, were derived from a marine sponge.<sup>2</sup> These molecules were the basis for synthesising some antiviral drugs, including the anti-HIV-1 drug zidovudine.<sup>2</sup> ANAs mimic the structure of nucleotides (the building block of RNA and DNA) and hence, inhibit or chain-terminate activity of viral polymerases. Consequently, they are among the essential antiviral drugs (> 25 FDA-approved drugs),<sup>5,7,8</sup> and some are on the World Health Organization's List of Essential Medicines. Moreover, an analogue developed for one virus can help treat emerging viruses. For example, the ANA remdesivir was initially developed for Ebola virus and rapidly repurposed to treat infections by SARS-CoV-2.<sup>9</sup>

Recently, it has been shown that several members of the radical S-adenosylmethionine (SAM) enzymes produce a range of ANAs. Two radical-SAM enzymes were shown to produce ANA albucidin.<sup>10</sup> We and others have shown<sup>11–13</sup> that a new class of the radical-SAM enzymes inaccurately called prokaryotic viperin<sup>14</sup>

and thus, renamed radical-SAM dependent nucleotide dehydratases (SANDs)<sup>14</sup> synthesise a range of new ANAs lacking 3'-hydroxyl group.

Members of the radical-SAM enzymes are widespread among all life forms<sup>11,15,16</sup> and have a highly conserved [4Fe–4S] cluster coordinated to three cysteine residues of the CxxxCxxC motif.<sup>17,18</sup> The [4Fe–4S]<sup>1+</sup> cluster reductively cleaves SAM generating the 5'-deoxyadenosyl radical (5'-dA\*) intermediate. In SANDs, the 5'-dA\* performs hydrogen atom transfer (HAT) from a nucleoside triphosphate (NTP) with an exquisite degree of selectivity, producing 3'-deoxy-3',4'-didehydro-NTPs like ddhUTP and ddhCTP (Fig. 1a). The ddhCTP analogue has antiviral activity against a large number of viruses and modulates the immune response.<sup>19,20</sup> Some fungal and microbial SANDs are shown to perform a similar chemical reaction synthesising ddhUTP, ddhCTP, and ddhGTP.<sup>12,13</sup> Therefore, SANDs or similar enzymes are a resource for discovering antiviral NPs to help develop new therapeutics.

To discover new enzymes or engineer existing SANDs and expand their chemical space for the synthesis of new ANAs, we perceived a novel assay named VITAS (Viral polymerase-Inhibition Toxin-Associated Selection) (Fig. 1b). The VITAS assay is based on the hypothesis that an ANA is formed due to the expression and activity of an enzyme in *E. coli*. The ANA inhibits viral T7 RNA polymerase (Pol)-mediated expression of a toxin protein allowing cell growth (Fig. 1b). The VITAS assay fundamentally differs from the commonly used live/dead assays in drug discovery. Traditional assays rely on chemical or biological labelling of cells during/after treatment with known purified lead molecules synthesised either chemically or using a purified enzyme. Moreover, purifying oxygen-sensitive radical-SAM enzymes is not straightforward, limiting the use of *in vitro* assays. These commonly used assays cannot easily be adopted for protein engineering to rapidly screen the activity of enzyme variants in a large library. In sharp contrast, the VITAS assay eliminates the need to purify enzymes and the NPs. Therefore, it enables the screening of enzymes' activity, facilitating the mining of the repository of natural enzymes and protein engineering to discover new ANAs. The VITAS assay is

Institute of Pharmaceutical Science, King's College London, London, UK.

E-mail: Kourosh.ebrahimi@kcl.ac.uk

 † Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cc00638g>




arabinose or IPTG concentrations (Fig. S2, ESI<sup>†</sup>) to modulate the hSAND and T7 RNA Pol expressions and activities or the LdrD expression and toxicity, respectively. When arabinose was not added (0.0% arabinose) to the LB-Agar plates (Fig. 3), the growth was the same within experimental error for the cells transformed with hSAND, LdrD or both hSAND and LdrD plasmids (Fig. 3). In the absence of arabinose, the growth was independent of the IPTG amount added to the LB medium (Fig. S2, ESI<sup>†</sup>). Therefore, the addition of arabinose is required to induce the T7 RNA Pol and the toxin LdrD expressions. The amount of arabinose could modulate the T7 RNA Pol activity and the LdrD expression and toxicity in the absence of IPTG (Fig. 3). The more the concentration of arabinose, the higher T7 RNA Pol expression and activity, thus, the more the LdrD expression and toxicity (Fig. 3). These observations are consistent with the fact that the T7 promoter is leaky.<sup>23</sup> As the arabinose concentration increased from 0.002% to 0.02%, the growth of hSAND-only expressing cells decreased (Fig. 3). A toxicity test showed that hSAND expression reduced *E. coli* growth (Fig. S3, ESI<sup>†</sup>). The hSAND expression in *E. coli* affects cell morphology.<sup>27</sup> These observations suggest that the hSAND overexpression is toxic to *E. coli* but significantly less than that of the LdrD overexpression (Fig. 3). At 0.02% arabinose with no IPTG added, the growth of LdrD-only expressing cells was almost entirely blocked. However, cells transformed with both hSAND and LdrD could grow (Fig. 3). We conclude that the nucleotide analogue ddhCTP produced by hSAND either directly or indirectly inhibits the activity of T7 RNA Pol and the synthesis of the functional toxin LdrD protein. This conclusion is consistent with earlier observations that hSAND expression in human cells suppresses T7 promoter-dependent RNA synthesis.<sup>28</sup>

After establishing the VITAS assay using human and fungal SANDs, we used the assay to identify new antiviral enzymes. As an example, we selected a putative bacterial SAND from *Pseudodesulfovibrio piezophilus* (PpSAND), which we predicted to be a homologue of TtSAND.<sup>11</sup> The AlphaFold-predicted structure of the enzyme (Fig. 4a) shows the CxxxCxxC motif forming the coordination environment required for the [4Fe-4S] cluster binding and the GGE motif of the SAM binding pocket (Fig. 4a). The expression of



Fig. 4 Discovery of a new SAND using the VITAS assay. (a) The AlphaFold-predicted structure of PpSAND. The predicted structure has the highly conserved CxxxCxxC motif to bind to the [4Fe-4S] cluster and the GGE motif of the SAM binding pocket. (b) The VITAS assay shows that a putative SAND enzyme from the bacterium *Pseudodesulfovibrio piezophilus* (PpSAND) produces an antiviral lead NP inhibiting activity of viral T7 RNA Pol. Data are the average of measurements using three biologically independent samples  $\pm$  standard deviations. (c) PpSAND contains a [4Fe-4S] cluster like TtSAND.

PpSAND by itself in *E. coli* did not cause toxicity (Fig. S4, ESI<sup>†</sup>). Next, we used the VITAS assay to screen the antiviral activity of PpSAND. We found that transforming cells with PpSAND and LdrD plasmids improved the growth of *E. coli* cells compared to the LdrD-only expressing cells (Fig. 4b). Therefore, PpSAND expression partially inhibited the T7 RNA Pol activity, reducing the LdrD expression. The ability of PpSAND to inhibit the T7 RNA Pol-mediated expression of LdrD and improve growth was affected by the concentration of IPTG (Fig. S5, ESI<sup>†</sup>), like what we observed for hSAND (Fig. S2, ESI<sup>†</sup>). At 1 mM IPTG, PpSAND was not able to inhibit the activity of T7 RNA Pol and the expression of toxin LdrD protein (Fig. 4b), unlike TtSAND (Fig. 2c). Additionally, the ability of PpSAND to rescue the *E. coli* growth was less than that of TtSAND. The exact reason for this observation is unclear. It could be because of: (i) the lower efficacy of the ANA produced by this enzyme, or (ii) its inefficient catalytic activity. The activity of PpSAND might be less due to the low soluble fraction of this protein inside *E. coli* cells. Although we could purify PpSAND (Fig. S6, ESI<sup>†</sup>) like TtSAND as we reported previously,<sup>24</sup> the protein solubility and purification could have been affected by lysis buffer or sonication. Alternatively, the low activity of PpSAND could be due to inefficient electron transfer from a yet-to-be-identified partner or [4Fe-4S] cluster transfer from the *E. coli* iron-sulfur biogenesis machinery. We used UV-visible spectroscopy to test the presence of [FeS] cluster in PpSAND. As a control, we measured the absorbance spectrum of TtSAND, which we previously confirmed to contain a [4Fe-4S] cluster.<sup>11,24</sup> The PpSAND UV-visible spectrum showed an absorbance peak around 405–410 nm, like TtSAND (Fig. 4c). These findings corroborate that PpSAND contains a [4Fe-4S] cluster. The amino acid blast analysis shows that PpSAND has several uncharacterised homologues in various organisms (Fig. S7, ESI<sup>†</sup>). Further studies using liquid




Fig. 3 hSAND inhibits T7 RNA Pol activity in the VITAS assay. The addition of arabinose is enough to induce the expression and toxicity of LdrD due to the leaky T7 promoter. Three different concentrations of arabinose in the LB-Agar plates were tested in the absence of IPTG. Data are the average of three independent replicates  $\pm$  standard deviations.



chromatography-mass spectrometry and NMR spectroscopy are required to identify and characterise the ANA produced by PpSAND.

In summary, we demonstrated the capabilities of the VITAS assay and its applicability to investigate fungi, humans, and bacteria enzymes producing ANAs. We tested only a single toxin protein LdrD. Likely, other types of toxins from type-I, -II, and -III can be used. The assay is sensitive to the activity of enzymes. Specifically, by varying the arabinose or IPTG concentration, we modulated the T7 RNA Pol expression and activity, thus, the LdrD expression and toxicity. Under varying arabinose or IPTG concentrations, each SAND showed a different response. It inhibited the T7 RNA Pol activity and the LdrD toxicity at a different level. Variation in the activity of enzymes could be due to multiple factors: (i) the difference in the efficacy of ANAs in blocking the viral T7 RNA Pol activity, (ii) the difference in electron transfer barrier<sup>29</sup> or [FeS] cluster transfer from the *E. coli* iron-sulfur biogenesis machinery leading to different catalytic efficiency, and/or (iii) variation in the soluble fraction of enzymes inside *E. coli* cells. Further work is required to explore each factor's contribution to *in vivo* activity, couple the assay to an LC-MS instrument, and modify it for high-throughput screening (HTS). We predict that the VITAS assay will facilitate the screening of enzyme variants to discover or engineer SANDs and other novel enzymes producing ANAs. The discovery of new enzymes is expected to help identify novel ANA NPs and expand the chemical space accessible for the enzymatic or chemoenzymatic synthesis of new antivirals.

KHE, Conceptualization, funding acquisition, and supervision; AFA, HK, DC, YJ, and MA, Data curation; KHE, writing the original draft with contribution from all co-authors; KHE, review & editing. KHE is grateful to Prof. Analise Pastore for generously dedicating her anaerobic glovebox to his lab. KHE thanks Dr Yvain Nicolet (ibs, France) for kindly providing pET28a vector and *E. coli* BL21-AI cells. This project was supported by King's College London student funds, the Royal Society International Exchange Grant (IES\R1\221117), and the Royal Society Research Grant (RGS\R1\231135) to KHE. All authors acknowledge the support from the European Cooperation in Science and Technology (COST) Action CA21115.

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- 1 C. J. Carlson, G. F. Albery, C. Merow, C. H. Trisos, C. M. Zipfel, E. A. Eskew, K. J. Olival, N. Ross and S. Bansal, *Nature*, 2022, **607**, 555–562.
- 2 V. Gogineni, R. F. Schinazi and M. T. Hamann, *Chem. Rev.*, 2015, **115**, 9655–9706.
- 3 J. Li, Y. Wang, X. Hao, S. Li, J. Jia, Y. Guan, Z. Peng, H. Bi, C. Xiao, S. Cen and M. Gan, *Molecules*, 2019, **24**, 2821.
- 4 F. I. Saldívar-González, V. D. Aldas-Bulos, J. L. Medina-Franco and F. Plisson, *Chem. Sci.*, 2022, **13**, 1526–1546.
- 5 L. P. Jordheim, D. Durantel, F. Zoulim and C. Dumontet, *Nat. Rev. Drug Discovery*, 2013, **12**, 447–464.
- 6 S. Mahmoud, S. Hasabelnaby, S. Hammad and T. Sakr, *J. Adv. Pharm. Res.*, 2018, **2**, 73–88.
- 7 U. Pradere, E. C. Garnier-Amblard, S. J. Coats, F. Amblard and R. F. Schinazi, *Chem. Rev.*, 2014, **114**, 9154–9218.
- 8 R. J. Geraghty, M. T. Aliota and L. F. Bonnac, *Viruses*, 2021, **13**, 667.
- 9 J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, H. Y. Chu, A. Luetkemeyer and S. Kline, *N. Engl. J. Med.*, 2020, **383**, 1813–1836.
- 10 P.-H. Fan, Y. Geng, A. J. Romo, A. Zhong, J. Zhang, Y.-C. Yeh, Y.-H. Lee and H.-W. Liu, *Angew. Chem., Int. Ed.*, 2022, **134**, e202210362.
- 11 K. H. Ebrahimi, J. Rowbotham, J. McCullagh and W. S. James, *ChemBioChem*, 2020, **21**, 1605–1612.
- 12 A. Bernheim, A. Millman, G. Ofir, G. Meitav, C. Avraham, H. Shomar, M. M. Rosenberg, N. Tal, S. Melamed, G. Amitai and R. Sorek, *Nature*, 2021, **589**, 120–124.
- 13 J. C. Lachowicz, A. S. Gizzi, S. C. Almo and T. L. Grove, *Biochemistry*, 2021, **60**, 2116–2129.
- 14 Y. Ji, W. Li, A. Da, H. Stark, P.-L. Hagedoorn, S. Ciofi-Baffoni, S. A. Cowley, R. O. Louro, S. Todorovic and M. A. Mroginiski, *Front. Mol. Biosci.*, 2022, **9**, 1032220.
- 15 K. H. Ebrahimi, D. Howie, J. Rowbotham, J. McCullagh, F. Armstrong and W. S. James, *FEBS Lett.*, 2020, **594**, 1624–1630.
- 16 M. K. Fenwick, Y. Li, P. Cresswell, Y. Modis and S. E. Ealick, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 6806–6811.
- 17 J. B. Broderick, B. R. Duffus, K. S. Duschene and E. M. Shepard, *Chem. Rev.*, 2014, **114**, 4229–4317.
- 18 K. H. Ebrahimi, *Metallomics*, 2018, **10**, 539–552.
- 19 K. H. Ebrahimi, S. Diofi, P. L. Hagedoorn, Y. Nicolet, N. E. Le Brun, W. R. Hagen and F. A. Armstrong, *Nat. Chem.*, 2022, **14**, 253–266.
- 20 S. Ghosh and E. N. G. Marsh, *J. Biol. Chem.*, 2020, **295**, 11513–11528.
- 21 L.-M. Guzman, D. Belin, M. J. Carson and J. O. N. Beckwith, *J. Bacteriol.*, 1995, **177**, 4121–4130.
- 22 M. Kawano, T. Oshima, H. Kasai and H. Mori, *Mol. Microbiol.*, 2002, **45**, 333–349.
- 23 G. J. Gopal and A. Kumar, *Protein J.*, 2013, **32**, 419–425.
- 24 K. H. Ebrahimi, S. B. Carr, J. McCullagh, J. Wickens, N. H. Rees, J. Cantley and F. Armstrong, *FEBS Lett.*, 2017, **591**, 2394–2405.
- 25 A. S. Gizzi, T. L. Grove, J. J. Arnold, J. Jose, R. K. Jangra, S. J. Garforth, Q. Du, S. M. Cahill, N. G. Dulyaninova, J. D. Love, K. Chandran, A. R. Brenick, C. E. Cameron and S. C. Almo, *Nature*, 2018, **558**, 610–614.
- 26 K. H. Ebrahimi, J. Vowles, C. Browne, J. McCullagh and W. S. James, *FEBS Lett.*, 2020, **594**, 1631–1644.
- 27 M. T. Nelp, A. P. Young, B. M. Stepanski and V. Bandarian, *Biochemistry*, 2017, **56**, 3874–3876.
- 28 A. Dukhovny, A. Shlomai and E. H. Sklan, *Sci. Rep.*, 2018, **8**, 8100.
- 29 F. D'Angelo, E. Fernández-Fueyo, P. S. Garcia, H. Shomar, M. Pelosse, R. R. Manuel, F. Büke, S. Liu, N. van den Broek and N. Duraffourg, *eLife*, 2022, **11**, e70936.

